Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System, which just received FDA clearance, and its CoolBlue(TM) System, please visit http://www.innercool.com.
Cardium also has two biologic candidates in clinical development.
Cardium's Tissue Repair Company subsidiary (TRC) is focused on the
development of growth factor therapeutics for the treatment of severe
chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is
a DNA-activated collagen gel for topical treatment formulated with an
adenovector delivery carrier encoding human platelet-derived growth
factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be
administered once or twice for the potential treatment of non-healing
diabetic foot ulcers. Other potential applications for TRC's Gene Activated
Matrix(TM) (GAM) technology include therapeutic angiogenesis
(cardiovascular ischemia, peripheral arterial disease) and orthopedic
products, including hard tissue (bone) and soft tissue (ligament, tendon,
cartilage) repair. For mor
|SOURCE Cardium Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved